Who Paid My Doc
William Grant
Podiatrist, Foot & Ankle Surgery Virginia Beach, VA Doctor of Podiatric Medicine
NPI 1982706685 CMS profile 316746
760 Independence Blvd, Suite 1, Virginia Beach, VA 23455
General payments
$271,014
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, William Grant of Virginia Beach, VA is reported in the CMS Open Payments database as having received $271,014 across 186 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $35,641 | 6 | |
| 2024 | General | $35,083 | 5 | |
| 2023 | General | $45,758 | 5 | |
| 2022 | General | $67,704 | 17 | |
| 2021 | General | $22,863 | 37 | |
| 2020 | General | $22,998 | 52 | |
| 2019 | General | $40,968 | 64 |
Beside peers
- William Grant
- Podiatrist, Foot & Ankle Surgery median
- Middle half of Podiatrist, Foot & Ankle Surgery
- National median
In program year 2025, general payments to William Grant were reported at $35,641. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.
Show as a table
| Year | William Grant | Podiatrist, Foot & Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $40,968 | $389 | $118–$1,406 | $163 |
| 2020 | $22,998 | $191 | $62–$691 | $114 |
| 2021 | $22,863 | $329 | $104–$1,341 | $132 |
| 2022 | $67,704 | $419 | $125–$1,611 | $149 |
| 2023 | $45,758 | $377 | $128–$1,164 | $160 |
| 2024 | $35,083 | $394 | $134–$1,168 | $164 |
| 2025 | $35,641 | $424 | $139–$1,306 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 24 drugsPart D claims
1,074
Drug cost
$13,566
Branded share of claims
19.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Fluorouracil | Generic | 28 | $2,461 | |
| Gabapentin | Generic | 127 | $1,462 | |
| Ciclopirox | Generic | 62 | $1,252 | |
| Terbinafine Hcl | Generic | 49 | $1,117 | |
| Ammonium Lactate | Generic | 52 | $1,063 | |
| Cephalexin | Generic | 64 | $849 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 48 | $597 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 87 | $573 | |
| Doxycycline Hyclate | Generic | 57 | $514 | |
| Ciclopirox Ciclopirox Olamine | Brand | 25 | $486 |
The 10 drugs with the highest cost, of 24 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 68 billing codesPaid by Medicare
$103,282
Medicare patients
280
Services billed
3,306
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 58% | |
| Diabetes | 54% | |
| Chronic kidney disease | 31% | |
| Ischemic heart disease | 26% | |
| Depression | 24% | |
| Heart failure | 19% | |
| COPD | 19% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 21 | 1,620 | $169 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 14 | 16 | $84 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 16 | 35 | $25 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 12 | 143 | $13 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
186 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot & Ankle Surgery in Virginia
Charles Zelen
Podiatrist, Foot & Ankle Surgery · Roanoke, VA
Ryan Vazales
Podiatrist, Foot & Ankle Surgery · Glen Allen, VA
Jugal Dharia
Podiatrist, Foot & Ankle Surgery · Fairfax, VA
William Simon
Podiatrist, Foot & Ankle Surgery · Virginia Beach, VA
Bradley Levitt
Podiatrist, Foot & Ankle Surgery · Virginia Beach, VA
Richard Derner
Podiatrist, Foot & Ankle Surgery · Lake Ridge, VA
Related records
Podiatrist, Foot & Ankle Surgery in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot & Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.